Drug Candidate | Target (Delivery) | Therapeutic Area | Discovery | IND enabling | Phase 1 | Phase 2 | Phase 3 | |
---|---|---|---|---|---|---|---|---|
Clinical Pipeline | ||||||||
NX-2127 Degrader | BTK + IKZF | B-cell malignancies |
| |||||
NX-5948 Degrader | BTK (Oral) | B-cell malignancies and autoimmune disease |
| |||||
NX-1607 Inhibitor | CBL-B (Oral) | Immuno-oncology |
| |||||
DeTIL-0255 Cell Therapy | Adoptive cell therapy with ex vivo CBL-B inhibition | Gynecologic malignancies |
| |||||
Drug Candidate | Target (Delivery) | Therapeutic Area | Discovery | IND enabling | Phase 1 | Phase 2 | Phase 3 | |
Discovery Pipeline | ||||||||
Wholly Owned | Multiple targets* | Undisclosed |
| |||||
Gilead Sciences | 5 targets | Undisclosed |
| |||||
Sanofi | 5 targets | Undisclosed |
|
Candidate / Target | Phase |
---|---|
Clinical Pipeline | NX-2127 Degrader BTK + IKZF | Phase 1 |
NX-5948 Degrader BTK (Oral) | Phase 1 |
NX-1607 Inhibitor CBL-B (Oral) | Phase 1 |
DeTIL-0255 Cell Therapy Adoptive cell therapy with ex vivo CBL-B inhibition | Phase 1 |
Discovery Pipeline | Wholly Owned Multiple targets* | Discovery |
Gilead Sciences 5 targets | Discovery |
Sanofi 5 targets | Discovery |
Degraders and inhibitors of multiple targets including E3 ligases, T cell kinase, hematology & oncology drivers, and viral proteins